Iruzid (Hydrochlorothiazide, Lisinopril)

Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting diuresis and reducing plasma volume. Lisinopril blocks the angiotensin‑converting enzyme, decreasing angiotensin II and aldosterone levels, which leads to vasodilation and lower systemic vascular resistance. Together they produce complementary antihypertensive effects.

The specific dose of Iruzid is determined by the prescribing clinician based on the patient’s blood pressure, renal function, and overall clinical condition. Dosage adjustments are made according to individual response and tolerability, following local prescribing guidelines.

Iruzid is classified as Pregnancy Category D, indicating evidence of fetal risk, and it should generally be avoided during pregnancy unless the potential benefit justifies the risk. Use while breastfeeding is not recommended because the drug may pass into breast milk and affect the infant.

To order Iruzid, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. The team then replies with pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Iruzid combines a thiazide diuretic and an ACE inhibitor in a single tablet, offering the convenience of dual therapy compared with prescribing two separate agents. This can improve adherence and provide synergistic blood‑pressure reduction, whereas alternatives such as calcium‑channel blocker monotherapy lack the diuretic component.

Store Iruzid at room temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Iruzid is taken orally, usually once daily, with or without food, as directed by the prescribing healthcare professional. Swallow the tablet whole with a full glass of water; do not crush or chew unless specifically instructed.

The most serious risks include angioedema, severe hypotension, acute kidney injury, hyperkalemia, and profound dehydration. Patients should be educated to seek immediate medical attention if they experience swelling of the face or throat, sudden dizziness, marked weakness, or a rapid decline in urine output.

Iruzid should not be used by individuals with known hypersensitivity to either hydrochlorothiazide or lisinopril, patients with severe renal impairment, those with a history of angioedema related to ACE‑inhibitor therapy, and pregnant women. Caution is also advised in patients with electrolyte disorders or severe liver disease.